Recent advances in targeted therapy of human myelogenous leukaemia

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 6, 2005, Pages 1147-1163

  Paz, Keren ^a   Zhu, Zhenping ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Bcr abl; Cd33; Farnesyl transferase; fms like tyrosine kinase 3 (flt3); Monoclonal antibody (mAb); Myelogenous leukaemia; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; ANTINEOPLASTIC AGENT; AVE 9633; BCR ABL PROTEIN; CD33 ANTIGEN; CEP 701; CETUXIMAB; CHIR 258; DASATINIB; DESATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLT3 LIGAND; GEFITINIB; GEMTUZUMAB OZOGAMICIN; GFKI 258; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IMC EB 10; LINTUZUMAB; LONAFARNIB; MIDOSTAURIN; MONOCLONAL ANTIBODY; NILOTINIB; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SUNITINIB; THIOGUANOSINE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAMYL;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANOREXIA; BONE MARROW HYPOPLASIA; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHILL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME BLOOD LEVEL; FATIGUE; FEVER; GENE MUTATION; GRANULOCYTOPENIA; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOTENSION; INFECTION COMPLICATION; LEUKEMOGENESIS; LEUKOPENIA; LIVER SINUSOID; LIVER TOXICITY; LUNG EMBOLISM; LYMPHOCYTOPENIA; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; PERIPHERAL NEUROPATHY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RASH; REVIEW; SIDE EFFECT; SINUSOIDAL OBSTRUCTIVE SYNDROME; SYNDROME; THROMBOCYTOPENIA; TRANSAMINITIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA, MYELOID; PROTEIN KINASE INHIBITORS;

EID: 28844454110     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.6.1147     Document Type: Review

References (183)

1. WINTON EF, LANGSTON AA: Update in acute leukemia 2003: a risk adapted approach to acute myeloblastic leukemia in adults. Semin. Oncol. (2004) 31:80-86.
2. VOUTSADAKIS IA: Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications. Med. Oncol. (2003) 20:311-324.
3. HEINRICH MC: Targeting FLT3 kinase in acute myelogenous leukemia: progress, perils, and prospects. Mini Rev. Med. Chem. (2004) 4:255-271.
4. DEININGER M, BUCHDUNGER E, DRUKER BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood (2005) 105:2640-2653.
5. COHEN MH, JOHNSON JR, PAZDUR R: US Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin. Cancer Res. (2005) 11:12-19.
6. LI S: Src kinases as targets for B cell acute lymphoblastic leukaemia therapy. Expert Opin. Ther. Targets (2005) 9:329-341.
7. VIGNOT S, FAIVRE S, AGUIRRE D, RAYMOND E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. (2005) 16:525-537.
8. TABERNERO J, ROJO F, MARIMON I et al.: Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. (2005) 23:2521-2533.
9. KARP JE, LANCET JE, KAUFMANN SH et al.: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a Phase I clinical-laboratory correlative trial. Blood (2001) 97:3361-3369.
10. JABBOUR E, KANTARJIAN H, CORTES J: Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk. Lymphoma (2004) 45:2187-2195.
11. MCLAUGHLIN F, LA THANGUE NB: Histone deacetylase inhibitors open new doors in cancer therapy. Biochem. Pharmacol. (2004) 68:1139-1144.
12. STADTMAUER EA: Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Curr. Oncol. Rep. (2002) 4:375-380.
13. HAMANN PR, HINMAN LM, HOLLANDER I et al.: Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. (2002) 13:47-58.
14. JURCIC JG: Antibody therapy of acute myelogenous leukemia. Cancer Biother. Radiopharm. (2000) 15:319-326.
15. JURCIC JG, CARON PC, NIKULA TK et al.: Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res. (1995) 55:5908s-5910s.
16. NG M, CUNNINGHAM D: Cetuximab (Erbitux)-an emerging targeted therapy for epidermal growth factor receptor-expressing tumours. Int. J. Clin. Pract. (2004) 58:970-976.
17. ERBITUX as a single agent and in combination in colorectal carcinoma. Expert Rev. Anti-Cancer Ther. (2002) 2:242.
18. HOCHHAUS A, KREIL S, CORBIN AS et al.: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia (2002) 16:2190-2196.
19. HOFMANN WK, KOMOR M, HOELZER D, OTTMANN OG: Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. Leuk. Lymphoma. (2004) 45:655-660.
20. GUMIREDDY K, BAKER SJ, COSENZA SC et al.: A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl. Acad. Sci. USA (2005) 102:1992-1997.
21. TRAVIS J: Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance. Science (2004) 305:319-321.
22. SHAH NP, TRAN C, LEE FY et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 305:399-401.
23. AGNES F, SHAMOON B, DINA C et al.: Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III. Gene (1994) 145:283-288.
24. ROSNET O, SCHIFF C, PEBUSQUE MJ et al.: Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood (1993) 82:1110-1119.
25. MATTHEWS W, JORDAN CT, WIEGAND GW et al.: A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell (1991) 65:1143-1152.
26. ROSNET O, MARCHETTO S, DELAPEYRIERE O, BIRNBAUM D: Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/ CSF1R family. Oncogene (1991) 6:1641-1650.
27. SMALL D, LEVENSTEIN M, KIM E et al.: STK-1, the human homolog of Flk-2/ Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc. Natl. Acad. Sci. USA (1994) 91:459-463.
28. DELAPEYRIERE O, NAQUET P, PLANCHE J et al.: Expression of Flt3 tyrosine kinase receptor gene in mouse hematopoietic and nervous tissues. Differentiation (1995) 58:351-359.
29. RAPPOLD I, ZIEGLER BL, KOHLER I et al.: Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood (1997) 90:111-125.
30. DOSIL M, WANG S, LEMISCHKA IR: Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol. Cell. Biol. (1993) 13:6572-6585.
31. ZHANG S, BROXMEYER HE: p85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells. Biochem. Biophys. Res. Commun. (1999) 254:440-445.
32. ZHANG S, BROXMEYER HE: Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase. Biochem. Biophys. Res. Commun. (2000) 277:195-199.
33. ZHANG S, MANTEL C, BROXMEYER HE: Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J. Leukoc. Biol. (1999) 65:372-380.
34. BRASEL K, ESCOBAR S, ANDERBERG R et al.: Expression of the flt3 receptor and its ligand on hematopoietic cells. Leukemia (1995) 9:1212-1218.
35. CAROW CE, LEVENSTEIN M, KAUFMANN SH et al.: Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood (1996) 87:1089-1096.
36. MEIERHOFF G, DEHMEL U, GRUSS HJ et al.: Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia (1995) 9:1368-1372.
37. ABU-DUHIER FM, GOODEVE AC, WILSON GA et al.: Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br. J. Haematol. (2001) 113:983-988.
38. NAKAO M, YOKOTA S, IWAI T et al.: Internal tandem duplication of the flk3 gene found in acute myeloid leukemia. Leukemia (1996) 10:1911-1918.
39. GILLILAND DG, GRIFFIN JD: The roles of FLT3 in hematopoiesis and leukemia. Blood (2002) 100:1532-1542.
40. KOTTARIDIS PD, GALE RE, FREW ME et al.: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood (2001) 98:1752-1759.
41. SCHNITTGER S, SCHOCH C, DUGAS M et al.: Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood (2002) 100:59-66.
42. THIEDE C, STEUDEL C, MOHR B et al.: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood (2002) 99:4326-4335.
43. HORIIKE S, YOKOTA S, NAKAO M et al.: Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia (1997) 11:1442-1446.
44. XU F, TAKI T, YANG HW et al.: Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br. J. Haematol. (1999) 105:155-162.
45. YOKOTA S, KIYOI H, NAKAO M et al.: Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia (1997) 11:1605-1609.
46. STIREWALT DL, KOPECKY KJ, MESHINCHI S et al.: FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood (2001) 97:3589-3595.
47. ABU-DUHIER FM, GOODEVE AC, WILSON GA et al.: FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br. J. Haematol. (2000) 111:190-195.
48. MESHINCHI S, WOODS WG, STIREWALT DL et al.: Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood (2001) 97:89-94.
49. BOISSEL N, CAYUELA JM, PREUDHOMME C et al.: Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia (2002) 16:1699-1704.
50. KIYOI H, NAOE T, NAKANO Y et al.: Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood (1999) 93:3074-3080.
51. ROMBOUTS WJ, BLOKLAND I, LOWENBERG B, PLOEMACHER RE: Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia (2000) 14:675-683.
52. WHITMAN SP, ARCHER KJ, FENG L et al.: Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. (2001) 61:7233-7239.
53. YAMAMOTO Y, KIYOI H, NAKANO Y et al.: Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood (2001) 97:2434-2439.
54. LEVIS M, ALLEBACH J, TSE KF et al.: A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood (2002) 99:3885-3891.
55. KELLY LM, YU JC, BOULTON CL et al.: CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell (2002) 1:421-432.
56. WEISBERG E, BOULTON C, KELLY LM et al.: Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell (2002) 1:433-443.
57. O'FARRELL AM, ABRAMS TJ, YUEN HA et al.: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood (2003) 101:3597-3605.
58. PILOTO O, LEVIS M, HUSO D et al.: Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice. Cancer Res. (2005) 65:1514-1522.
59. LI Y, LI H, WANG MN et al.: Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood (2004) 104:1137-1144.
60. SAWYERS CL: Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell (2002) 1:413-415.
61. YEE KW, O'FARRELL AM, SMOLICH BD et al.: SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood (2002) 100:2941-2949.
62. SOHAL J, PHAN VT, CHAN PV et al.: A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood (2003) 101:3188-3197.
63. MIKNYOCZKI SJ, CHANG H, KLEIN-SZANTO A et al.: The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin. Cancer Res. (1999) 5:2205-2212.
64. GEORGE DJ, DIONNE CA, JANI J et al.: Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res. (1999) 59:2395-2401.
65. SMITH BD, LEVIS M, BERAN M et al.: Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood (2004) 103:3669-3676.
66. PANDEY A, VOLKOTS DL, SEROOGY JM et al.: Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J. Med. Chem. (2002) 45:3772-3793.
67. MARTE BM, MEYER T, STABEL S et al.: Protein kinase C and mammary cell differentiation: involvement of protein kinase C alpha in the induction of betacasein expression. Cell Growth Differ. (1994) 5:239-247.
68. STONE RM, DE ANGELO J, GALINSKY I et al.: PKC 412 FLT3 inhibitor therapy in AML: results of a Phase II trial. Ann. Hematol. (2004) 83(Suppl. 1):S89-S90.
69. FONG TA, SHAWVER LK, SUN L et al.: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. (1999) 59:99-106.
70. SRIDHAR SS, SHEPHERD FA: Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer. (2003) 42(Suppl. 1):S81-S91.
71. ANTONIAN L, ZHANG H, YANG C et al.: Biotransformation of the anti-angiogenic compound SU5416. Drug Metab. Dispos. (2000) 28:1505-1512.
72. KUENEN BC, ROSEN L, SMIT EF et al.: Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. (2002) 20:1657-1667.
73. STOPECK A, SHELDON M, VAHEDIAN M et al.: Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin. Cancer Res. (2002) 8:2798-2805.
74. ZHAO Y, YANG CY, HAZNEDAR J, ANTONIAN L: Simultaneous determination of SU5416 and its Phase I and Phase II metabolites in rat and dog plasma by LC/MS/MS. J. Pharm. Biomed. Anal. (2001) 25:821-832.
75. FIEDLER W, MESTERS R, TINNEFELD H et al.: A Phase II clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood (2003) 102:2763-2767.
76. GILES FJ, STOPECK AT, SILVERMAN LR et al.: SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood (2003) 102:795-801.
77. HEYMACH JV, DESAI J, MANOLA J et al.: Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas, Clin. Cancer Res. (2004) 10:5732-5740.
78. MESTERS RM, PADRO T, BIEKER R et al.: Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood (2001) 98:241-243.
79. PETERSON AC, SWIGER S, STADLER WM et al.: Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin. Cancer Res. (2004) 10:4048-4054.
80. STADLER WM, CAO D, VOGELZANG NJ et al.: A randomized Phase Il trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin. Cancer Res. (2004) 10:3365-3370.
81. ZANGARI M, ANAISSIE E, STOPECK A et al.: Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin. Cancer Res. (2004) 10:88-95.
82. SISTLA A, SUNGA A, PHUNG K et al.: Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trials. Drug Dev. Ind. Pharm. (2004) 30:19-25.
83. ABRAMS TJ, LEE LB, MURRAY LJ et al.: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. (2003) 2:471-478.
84. BARATTE S, SARATI S, FRIGERIO E et al.: Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J. Chromatogr. A. (2004) 1024:87-94.
85. LAIRD AD, CHERRINGTON JM: Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin. Investig. Drugs (2003) 12:51-64.
86. MENDEL DB, LAIRD AD, XIN X et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin. Cancer Res. (2003) 9:327-337.
87. ABRAMS TJ, MURRAY LJ, PESENTI E et al.: Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with 'standard of care' therapeutic agents for the treatment of breast cancer. Mol. Cancer Ther. (2003) 2:1011-1021.
88. FIEDLER W. SERVE H, DOHNER H et al.: A Phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood (2005) 105:986-993.
89. O'FARRELL AM, FORAN JM, FIEDLER W et al.: An innovative Phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. (2003) 9:5465-5476.
90. WILLIAMS B, ATKINS A, ZHANG H et al.: Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth. Leukemia (2005) 19:1432-1438.
91. LI Y, ZHU Z: Antibody-based therapeutics to FLT3 for leukemia therapy. Int. J. Hematology (2005). 82:108-114.
92. CROCKER PR: Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling. Curr. Opin. Struct. Biol. (2002) 12:609-615.
93. FREEMAN SD, KELM S, BARBER EK, CROCKER PR: Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood (1995) 85:2005-2012.
94. BRINKMAN-VAN DER LINDEN EC, VARKI A. New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins. J. Biol. Chem. (2000) 275:8625-8632.
95. TAYLOR VC, BUCKLEY CD, DOUGLAS M et al.: The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J. Biol. Chem. (1999) 274:11505-11512.
96. DINNDORF PA, ANDREWS RG, BENJAMIN D et al.: Expression of normal myeloid-associated antigens by acute leukemia cells. Blood (1986) 67:1048-1053.
97. RAVANDI F, KANTARJIAN H, GILES F, CORTES J: New agents in acute myeloid leukemia and other myeloid disorders. Cancer (2004) 100:441-454.
98. BROSS PF, BEITZ J, CHEN G et al.: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. (2001) 7:1490-1496.
99. SIEVERS EL, APPELBAUM FR, SPIELBERGER RT et al.: Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a Phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood (1999) 93:3678-3684.
100. APPELBAUM FR: Antibody-targeted therapy for myeloid leukemia. Semin. Hematol. (1999) 36:2-8.
101. GILES F, ESTEY E, O'BRIEN S: Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer (2003) 98:2095-2104.
102. VAN DER VELDEN VH, TE MARVELDE JG, HOOGEVEEN PG et al.: Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood (2001) 97:3197-3204.
103. GOLAY J, DI GAETANO N, AMICO D et al.: Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br. J. Haematol. (2005) 128:310-317.
104. LINENBERGER ML: CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia (2005) 19:176-182.
105. WALTER RB, RADEN BW, KAMIKURA DM et al.: Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood (2005) 105:1295-1302.
106. SIEVERS EL, LARSON RA, STADTMAUER EA et al.: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. (2001) 19:3244-3254.
107. KELL WJ, BURNETT AK, CHOPRA R et al.: A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood (2003) 102:4277-4293.
108. CO MS, AVDALOVIC NM, CARON PC et al.: Chimeric and humanized antibodies with specificity for the CD33 antigen. J. Immunol. (1992) 148:1149-1154.
109. CARON PC, JURCIC JG, SCOTT AM et al.: A Phase IB trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood (1994) 83:1760-1768.
110. CO MS, SCHEINBERG DA, AVDALOVIC NM et al.: Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody. Mol. Immunol. (1993) 30:1361-1367.
111. CARON PC, DUMONT L, SCHEINBERG DA: Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin. Cancer Res. (1998) 4:1421-1428.
112. FELDMAN E, KALAYCIO M, WEINER G et al.: Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia (2003) 17:314-318.
113. FELDMAN EJ, BRANDWEIN J, STONE R et al.: Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myelold leukemia. J. Clin. Oncol. (2005) 23:4110-4116.
114. BURKE JM, CARON PC, PAPADOPOULOS EB et al.: Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. (2003) 32:549-556.
115. JURCIC JG, LARSON SM, SGOUROS G et al.: Targeted alpha particle immunotherapy for myeloid leukemia. Blood (2002) 100:1233-1239.
116. MCDEVITT MR, FINN RD, MA D et al.: Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. J. Nucl. Med. (1999) 40:1722-1727.
117. MCDEVITT MR, FINN RD, SCOUROS G et al.: An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation. Appl. Radiat. Isot. (1999) 50:895-904.
118. MIEDERER M, MCDEVITT MR, SGOUROS G et al.: Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J. Nucl. Med. (2004) 45:129-137.
119. DENNY WA: Tumor-activated prodrugs-a new approach to cancer therapy. Cancer Invest. (2004) 22:604-619.
120. REISS Y, GOLDSTEIN JL, SEABRA MC et al.: Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell (1990) 62:81-88.
121. ROWINSKY EK, WINDLE JJ, VON HOFF DD: Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J. Clin. Oncol. (1999) 17:3631-3652.
122. SINENSKY M, LUTZ RJ: The prenylation of proteins. Bioessays (1992) 14:25-31.
123. COX AD, DER CJ: Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta. (1997) 1333:F51-F71.
124. LEBOWITZ PF, PRENDERGAST GC: Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene (1998) 17:1439-1445.
125. PRENDERGAST GC: Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology. Histol. Histopathol. (2001) 16:269-275.
126. BRITTEN CD, ROWINSKY EK, SOIGNET S et al.: A Phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin. Cancer Res. (2001) 7:3894-3903.
127. MANNE V, YAN N, CARBONI JM et al.: Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene (1995) 10:1763-1779.
128. BRODSKY AL: Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line. Blood (2003) 101:2070; author reply 2070-2071.
129. END DW, SMETS G, TODD AV et al.: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. (2001) 61:131-137.
130. JOHNSTON SR: BMS-214662 (Bristol-Myers Squibb). IDrugs (2003) 6:72-78.
131. CAPONIGRO F, CASALE M, BRYCE J: Farnesyl transferase inhibitors in clinical development. Expert Opin. Investig. Drugs (2003) 12:943-954.
132. REICHERT A, HEISTERKAMP N, DALEY GQ, GROFFEN J: Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood (2001) 97:1399-1403.
133. LANCET JE, KARP JE: Farnesyl transferase inhibitors in myeloid malignancies. Blood Rev. (2003) 17:123-129.
134. CORTES J, ALBITAR M, THOMAS D et al.: Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood (2003) 101:1692-1697.
135. LIU M, BRYANT MS, CHEN J et al.: Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. (1998) 58:4947-4956.
136. PETERS DG, HOOVER RR, GERLACH MJ et al.: Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood (2001) 97:1404-1412.
137. HOOVER RR, MAHON FX, MELO JV, DALEY GQ: Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood (2002) 100:1068-1071.
138. ROSE WC, LEE FY, FAIRCHILD CR et al.: Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. (2001) 61:7507-7517.
139. GOMEZ-BENITO M, MARZO I, ANEL A, NAVAL J: Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination. Mol. Pharmacol. (2005) 67:1991-1998.
140. CORTES J, FADERL S, ESTEY E et al.: Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J. Clin. Oncol. (2005) 23:2805-2812.
141. SAWYERS CL: Chronic myeloid leukemia. N. Engl. J. Med. (1999) 340:1330-1340.
142. VARDIMAN JW, HARRIS NL, BRUNNING RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood (2002) 100:2292-2302.
143. GILES FJ, CORTES JE, KANTARJIAN HM, O'BRIEN SM: Accelerated and blastic phases of chronic myelogenous leukemia. Hematol. Oncol. Clin. North Am. (2004) 18:753-774, xii.
144. CLIFT RA, RADICH J, APPELBAUM FR et al.: Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood (1999) 94:3960-3962.
145. HOROWITZ MM, ROWLINGS PA, PASSWEG JR: Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. (1996) 17(Suppl. 3):S5-S6.
146. VAN RHEE F, SZYDLO RM, HERMANS J et al.: Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. (1997) 20:553-560.
147. KURZROCK R, KANTARJIAN HM, DRUKER BJ, TALPAZ M: Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann. Intern. Med. (2003) 138:819-830.
148. OHSAKA A, SHIINA S, KOBAYASHI M et al.: Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCR-ABL). Intern. Med. (2002) 41:1183-1187.
149. WONG S, WITTE ON: Modeling Philadelphia chromosome positive leukemias. Oncogene (2001) 20:5644-5659.
150. LANEUVILLE P: Abl tyrosine protein kinase. Semin. Immunol. (1995) 7:255-266.
151. LUGO TG, PENDERGAST AM, MULLER AJ, WITTE ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (1990) 247:1079-1082.
152. PLATTNER R, PENDERGAST AM: Activation and signaling of the Abl tyrosine kinase: bidirectional link with phosphoinositide signaling. Cell Cycle (2003) 2:273-274.
153. WANG JY. Regulation of cell death by the Abl tyrosine kinase. Oncogene (2000) 19:5643-5650.
154. LANIER LM, GERTLER FB: From Abl to actin. Abl tyrosine kinase and associated proteins in growth cone motility. Curr. Opin. Neurobiol. (2000) 10:80-87.
155. REN R: Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer (2005) 5:172-183.
156. BUCHDUNGER E, ZIMMERMANN J, METT H et al.: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. (1996) 56:100-104.
157. DRUKER BJ, TAMURA S, BUCHDUNGER E et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. (1996) 2:561-566.
158. BERAN M, CAO X, ESTROV Z et al.: Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin. Cancer Res. (1998) 4:1661-1672.
159. DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344:1031-1037.
160. DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. (2001) 344:1038-1042.
161. TALPAZ M, SILVER RT, DRUKER BJ et al.: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase II study. Blood (2002) 99:1928-1937.
162. LA ROSEE P, O'DWYER ME, DRUKER BJ: Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia (2002) 16:1213-1219.
163. GORRE ME, MOHAMMED M, ELLWOOD K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 293:876-880.
164. MOHAMED AN, PEMBERTON P, ZONDER J, SCHIFFER CA: The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res. (2003) 9:1333-1337.
165. NAGAR B, BORNMANN WG, PELLICENA P et al.: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. (2002) 62:4236-4243.
166. SCHINDLER T, BORNMANN W, PELLICENA P et al.: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 289:1938-1942.
167. O'HARE T, WALTERS DK, DEININGER MW, DRUKER BJ: AMN 107: tightening the grip of imatinib. Cancer Cell (2005) 7:117-119.
168. WEISBERG E, MANLEY PW, BREITENSTEIN W et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7:129-141.
169. O'HARE T, WALTERS DK, STOFFREGEN EP et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. (2005) 65:4500-4505.
170. PENG B, HAYES M, RESTA D et al.: Pharmacokinetics and pharmacodynamics of imatinib in a Phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. (2004) 22:935-942.
171. DOGGRELL SA. BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. Expert Opin. Investig. Drugs (2005) 14:89-91.
172. GAMBACORTI-PASSERINI C, GASSER M, AHMED S et al.: Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia (2005).
173. Oral BMS-354825 rescues Gleevec-resistant CML. Cancer Biol Ther. (2004) 3:700.
174. LOMBARDO LJ, LEE FY, CHEN P et al.: Discovery of N-(2-chloro-6-methylphenyl) -2-(6-(4-(2-hydroxyethyl)-piperazi-1 -yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. (2004) 47:6658-6661.
175. PAEZ JG, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304:1497-1500.
176. PAO W, MILLER V, ZAKOWSKI M et al.: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA (2004) 101:13306-13311.
177. SORDELLA R, BELL DW, HABER DA, SETTLEMAN J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (2004) 305:1163-1167.
178. LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350:2129-2139.
179. FABIAN MA, BIGGS WH, 3RD, TREIBER DK et al.: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. (2005) 23:329-336.
180. DIAS S, HATTORI K, HEISSIG B et al.: Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc. Natl. Acad. Sci. USA (2001) 98:10857-10862.
181. DIAS S, HATTORI K, ZHU Z et al.: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. (2000) 106:511-521.
182. ZHANG H, LI Y, LI H et al.: Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2. Leuk. Lymphoma (2004) 45:1887-1897.
183. ZHU Z, HATTORI K, ZHANG H et al.: Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia (2003) 17:604-611.